recombinant mouse il 33 carrier free Search Results


95
Revvity recombinant mouse gm csf carrier free
Recombinant Mouse Gm Csf Carrier Free, supplied by Revvity, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse gm csf carrier free/product/Revvity
Average 95 stars, based on 1 article reviews
recombinant mouse gm csf carrier free - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

95
R&D Systems il 33 3626 ml
Il 33 3626 Ml, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 33 3626 ml/product/R&D Systems
Average 95 stars, based on 1 article reviews
il 33 3626 ml - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

93
Boster Bio il 33
Il 33, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 33/product/Boster Bio
Average 93 stars, based on 1 article reviews
il 33 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
R&D Systems recombinant mouse il 33
<t>IL-33</t> expression in acute experimental and clinical liver fibrosis. (a) The <t>hepatic</t> <t>IL-33</t> expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).
Recombinant Mouse Il 33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse il 33/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant mouse il 33 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
R&D Systems recombinant il 33 carrier free
<t>IL-33</t> expression in acute experimental and clinical liver fibrosis. (a) The <t>hepatic</t> <t>IL-33</t> expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).
Recombinant Il 33 Carrier Free, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant il 33 carrier free/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant il 33 carrier free - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

92
R&D Systems intranasal mil
<t>IL-33</t> expression in acute experimental and clinical liver fibrosis. (a) The <t>hepatic</t> <t>IL-33</t> expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).
Intranasal Mil, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/intranasal mil/product/R&D Systems
Average 92 stars, based on 1 article reviews
intranasal mil - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

90
Biosearch Technologies Inc recombinant human il-18
<t>IL-33</t> expression in acute experimental and clinical liver fibrosis. (a) The <t>hepatic</t> <t>IL-33</t> expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).
Recombinant Human Il 18, supplied by Biosearch Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il-18/product/Biosearch Technologies Inc
Average 90 stars, based on 1 article reviews
recombinant human il-18 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Jackson Laboratory 10g of carrier-free recombinant mouse ifn
<t>IL-33</t> expression in acute experimental and clinical liver fibrosis. (a) The <t>hepatic</t> <t>IL-33</t> expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).
10g Of Carrier Free Recombinant Mouse Ifn, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/10g of carrier-free recombinant mouse ifn/product/Jackson Laboratory
Average 90 stars, based on 1 article reviews
10g of carrier-free recombinant mouse ifn - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
PBL Assay recombinant murine ifn-ß (mouse interferon beta, mammalian, carrier-free)
<t>IL-33</t> expression in acute experimental and clinical liver fibrosis. (a) The <t>hepatic</t> <t>IL-33</t> expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).
Recombinant Murine Ifn ß (Mouse Interferon Beta, Mammalian, Carrier Free), supplied by PBL Assay, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant murine ifn-ß (mouse interferon beta, mammalian, carrier-free)/product/PBL Assay
Average 90 stars, based on 1 article reviews
recombinant murine ifn-ß (mouse interferon beta, mammalian, carrier-free) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
PBL Assay carrier-free recombinant mouse ifn-β
<t>IL-33</t> expression in acute experimental and clinical liver fibrosis. (a) The <t>hepatic</t> <t>IL-33</t> expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).
Carrier Free Recombinant Mouse Ifn β, supplied by PBL Assay, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/carrier-free recombinant mouse ifn-β/product/PBL Assay
Average 90 stars, based on 1 article reviews
carrier-free recombinant mouse ifn-β - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
PeproTech endotoxin-free recombinant mouse il-28 (ifn-λ)
<t>IL-33</t> expression in acute experimental and clinical liver fibrosis. (a) The <t>hepatic</t> <t>IL-33</t> expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).
Endotoxin Free Recombinant Mouse Il 28 (Ifn λ), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/endotoxin-free recombinant mouse il-28 (ifn-λ)/product/PeproTech
Average 90 stars, based on 1 article reviews
endotoxin-free recombinant mouse il-28 (ifn-λ) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
TransGen biotech co recombinant murine il-33
Survival rate of mice in sham operation, <t>model,</t> <t>IL-33</t> -/- , and IL-33 -/- intervention groups. Survival rate of mice in sham operation, model, IL-33 -/- , andIL-33 -/- intervention groups (n = 7). Survival rate of mice in sham operation, model, IL-33 -/- , and IL-33 -/- intervention groups (n = 7); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.
Recombinant Murine Il 33, supplied by TransGen biotech co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant murine il-33/product/TransGen biotech co
Average 90 stars, based on 1 article reviews
recombinant murine il-33 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


IL-33 expression in acute experimental and clinical liver fibrosis. (a) The hepatic IL-33 expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).

Journal: Cellular and Molecular Immunology

Article Title: Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells

doi: 10.1038/cmi.2016.63

Figure Lengend Snippet: IL-33 expression in acute experimental and clinical liver fibrosis. (a) The hepatic IL-33 expression following bile-duct ligation (BDL) was assessed in C57BL/6 mice at several time points by real-time PCR and western blot, and (b) IL-33 serum levels were determined by ELISA. Mean values±s.e.m. are given of two independent studies with groups of eight mice (*P<0.05, **P <0.01, ***P <0.001). (c) IL-33 in human liver tissue homogenates (ELISA) after partial hepatectomy of early-stage hepatocellular carcinoma with fibrosis or controls with hepatic hemangioma. The data are expressed as the median and range (0, 25, 50, 75 and 100%) from 24 fibrotic and 20 normal liver tissues (***P <0.001). (d) Cellular expression of IL-33 in fibrotic human livers was identified by immunofluorescence (IF) using FITC-labeled anti huIL-33 antibody, PE-labeled CK-19 (cholangiocytes), PE-labeled GFAP (HSC) or PE-labeled albumin (hepatocytes). Nuclei were counterstained with DAPI (magnification × 400, scale bar, 50 μm).

Article Snippet: In preliminary trials, mice were given an intraperitoneal injection of recombinant mouse IL-33 (1, 5 or 10 μg per day, R&D Systems, Abingdon, UK) 3 days before BDL, and 5 μg was finally used in the experiments.

Techniques: Expressing, Ligation, Real-time Polymerase Chain Reaction, Western Blot, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Labeling

BDL-induced liver injury and fibrosis are reduced in the absence of ST2. Liver injury following bile-duct ligation (BDL) was analyzed in C57BL/6 and ST2-deficient (KO) mice. (a) Macro- and microphotographs demonstrate attenuated liver inflammation, necrosis and fibrosis in ST2-KO mice (H&E and Masson staining, original magnification × 200). (b) Serum alanine aminotransferase and aspartate aminotransferase at 0, 1, 3, 10 and 21 days after BDL. (c) Inflammation was assessed in liver homogenates of C57BL/6 and IL-33/ST2-KO mice at 0, 1, 3, 10 and 21 days after BDL. IL-1β, KC and thymic stromal lymphopoietin were reduced in ST2-KO mice compared with C57BL/6 mice. (d) Hepatic collagen expression was assessed with a Sircol assay and real-time PCR for collagen 1a1. The data are expressed as median values±s.e.m. (n=6–8 mice/group) and are representative of three independent experiments (*P<0.05, **P<0.01, ***P<0.001).

Journal: Cellular and Molecular Immunology

Article Title: Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells

doi: 10.1038/cmi.2016.63

Figure Lengend Snippet: BDL-induced liver injury and fibrosis are reduced in the absence of ST2. Liver injury following bile-duct ligation (BDL) was analyzed in C57BL/6 and ST2-deficient (KO) mice. (a) Macro- and microphotographs demonstrate attenuated liver inflammation, necrosis and fibrosis in ST2-KO mice (H&E and Masson staining, original magnification × 200). (b) Serum alanine aminotransferase and aspartate aminotransferase at 0, 1, 3, 10 and 21 days after BDL. (c) Inflammation was assessed in liver homogenates of C57BL/6 and IL-33/ST2-KO mice at 0, 1, 3, 10 and 21 days after BDL. IL-1β, KC and thymic stromal lymphopoietin were reduced in ST2-KO mice compared with C57BL/6 mice. (d) Hepatic collagen expression was assessed with a Sircol assay and real-time PCR for collagen 1a1. The data are expressed as median values±s.e.m. (n=6–8 mice/group) and are representative of three independent experiments (*P<0.05, **P<0.01, ***P<0.001).

Article Snippet: In preliminary trials, mice were given an intraperitoneal injection of recombinant mouse IL-33 (1, 5 or 10 μg per day, R&D Systems, Abingdon, UK) 3 days before BDL, and 5 μg was finally used in the experiments.

Techniques: Ligation, Staining, Expressing, Real-time Polymerase Chain Reaction

Recombinant IL-33 exacerbates inflammation in C57BL/6 mice. Recombinant mouse IL-33 was injected 3 days before BDL (intraperitoneally at 5 μg per day) into C57BL/6 mice. (a) Serum alanine aminotransferase and aspartate aminotransferase levels from WT BL6 mice without or with rmIL-33 (0 μg, 1 μg, 5 μg and 10 μg) at 1 day. The data are expressed as the mean values±s.e.m. (n=6–8 mice/group; (a) values are significantly different from the BL6 sham group; (b) not significantly different from the 5 μg IL-33 group). (b and c) Increased liver injury and inflammation, as assessed by hematoxylin and eosin staining, myeloperoxidase and Suzuki score. (d) Hepatic IL-1β, thymic stromal lymphopoietin and granulocyte-macrophage colony stimulating factor were increased. The data are expressed as the mean values±s.e.m. (n=6–8 mice/group) and are representative of three independent experiments (*P<0.05; **P<0.01; ns, not significant).

Journal: Cellular and Molecular Immunology

Article Title: Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells

doi: 10.1038/cmi.2016.63

Figure Lengend Snippet: Recombinant IL-33 exacerbates inflammation in C57BL/6 mice. Recombinant mouse IL-33 was injected 3 days before BDL (intraperitoneally at 5 μg per day) into C57BL/6 mice. (a) Serum alanine aminotransferase and aspartate aminotransferase levels from WT BL6 mice without or with rmIL-33 (0 μg, 1 μg, 5 μg and 10 μg) at 1 day. The data are expressed as the mean values±s.e.m. (n=6–8 mice/group; (a) values are significantly different from the BL6 sham group; (b) not significantly different from the 5 μg IL-33 group). (b and c) Increased liver injury and inflammation, as assessed by hematoxylin and eosin staining, myeloperoxidase and Suzuki score. (d) Hepatic IL-1β, thymic stromal lymphopoietin and granulocyte-macrophage colony stimulating factor were increased. The data are expressed as the mean values±s.e.m. (n=6–8 mice/group) and are representative of three independent experiments (*P<0.05; **P<0.01; ns, not significant).

Article Snippet: In preliminary trials, mice were given an intraperitoneal injection of recombinant mouse IL-33 (1, 5 or 10 μg per day, R&D Systems, Abingdon, UK) 3 days before BDL, and 5 μg was finally used in the experiments.

Techniques: Recombinant, Injection, Staining

IL-33 activates hepatic stellate cells (HSCs) via mitogen-activated protein kinases signaling. Mouse HSCs were isolated from naive C57BL/6 and ST2-KO mice and activated with rmuIL-33 in vitro (0, 1, 10, 50 or 100 ng/ml). IL-6, TGF-β, α-SMA RNA transcription and soluble collagen in the supernatant were increased at 24 h (a–d). HSCs expressed increased phosphorylated JNK, ERK or p38 on activation by rmuIL-33 at 24 h, which was ST2-dependent. Levels of JNK, ERK or p38 phosphorylation were quantified by ImageJ software (e). The JNK inhibitor SP600125, ERK/MEK1 inhibitor PD98059, or p38 inhibitor SB203580 were given 1 h before rmIL-33 at 100 ng/ml and inhibited collagen production, as measured by Sircol assay (f). Mean values±s.e.m. of a representative study of three independent experiments are shown; comparisons between subgroups were performed by one-way ANOVA followed by a Newman–Keuls posttest: *P<0.05, **P<0.01, ***P<0.001 (compared with cells cultured in medium).

Journal: Cellular and Molecular Immunology

Article Title: Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells

doi: 10.1038/cmi.2016.63

Figure Lengend Snippet: IL-33 activates hepatic stellate cells (HSCs) via mitogen-activated protein kinases signaling. Mouse HSCs were isolated from naive C57BL/6 and ST2-KO mice and activated with rmuIL-33 in vitro (0, 1, 10, 50 or 100 ng/ml). IL-6, TGF-β, α-SMA RNA transcription and soluble collagen in the supernatant were increased at 24 h (a–d). HSCs expressed increased phosphorylated JNK, ERK or p38 on activation by rmuIL-33 at 24 h, which was ST2-dependent. Levels of JNK, ERK or p38 phosphorylation were quantified by ImageJ software (e). The JNK inhibitor SP600125, ERK/MEK1 inhibitor PD98059, or p38 inhibitor SB203580 were given 1 h before rmIL-33 at 100 ng/ml and inhibited collagen production, as measured by Sircol assay (f). Mean values±s.e.m. of a representative study of three independent experiments are shown; comparisons between subgroups were performed by one-way ANOVA followed by a Newman–Keuls posttest: *P<0.05, **P<0.01, ***P<0.001 (compared with cells cultured in medium).

Article Snippet: In preliminary trials, mice were given an intraperitoneal injection of recombinant mouse IL-33 (1, 5 or 10 μg per day, R&D Systems, Abingdon, UK) 3 days before BDL, and 5 μg was finally used in the experiments.

Techniques: Isolation, In Vitro, Activation Assay, Software, Cell Culture

Survival rate of mice in sham operation, model, IL-33 -/- , and IL-33 -/- intervention groups. Survival rate of mice in sham operation, model, IL-33 -/- , andIL-33 -/- intervention groups (n = 7). Survival rate of mice in sham operation, model, IL-33 -/- , and IL-33 -/- intervention groups (n = 7); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Journal: Acta Cirúrgica Brasileira

Article Title: Effect of IL-33 on pyroptosis of macrophages in mice with sepsis via NF-κB/p38 MAPK signaling pathway

doi: 10.1590/ACB360501

Figure Lengend Snippet: Survival rate of mice in sham operation, model, IL-33 -/- , and IL-33 -/- intervention groups. Survival rate of mice in sham operation, model, IL-33 -/- , andIL-33 -/- intervention groups (n = 7). Survival rate of mice in sham operation, model, IL-33 -/- , and IL-33 -/- intervention groups (n = 7); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Article Snippet: After operation, recombinant murine IL-33 (TransGen Biotech™, Beijing, China) was intraperitoneally injected into the mice at 0.5 mg/kg in the IL-33 -/- intervention group, while the same volume of normal saline was injected into the mice in the model group, the sham operation group, and the IL-33 -/- group.

Techniques:

Macrophage identification and mRNA expression level of IL-33 in mice peritoneal lavage fluid. (a) Immunofluorescence to detect CD11b expression in peritoneal lavage fluid; (b) mRNA expression level of IL-33 in sham operation, model,IL-33 -/- , and IL-33 -/- intervention groups (n = 5); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Journal: Acta Cirúrgica Brasileira

Article Title: Effect of IL-33 on pyroptosis of macrophages in mice with sepsis via NF-κB/p38 MAPK signaling pathway

doi: 10.1590/ACB360501

Figure Lengend Snippet: Macrophage identification and mRNA expression level of IL-33 in mice peritoneal lavage fluid. (a) Immunofluorescence to detect CD11b expression in peritoneal lavage fluid; (b) mRNA expression level of IL-33 in sham operation, model,IL-33 -/- , and IL-33 -/- intervention groups (n = 5); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Article Snippet: After operation, recombinant murine IL-33 (TransGen Biotech™, Beijing, China) was intraperitoneally injected into the mice at 0.5 mg/kg in the IL-33 -/- intervention group, while the same volume of normal saline was injected into the mice in the model group, the sham operation group, and the IL-33 -/- group.

Techniques: Expressing, Immunofluorescence

Content of inflammatory factors detected via ELISA. (a) Content of IL-33; (b) Content of IL-1β; (c) content of IL-18. Content of IL-33,IL-1β, and IL-18 in the serum of mice in sham operation, model, IL-33 -/- , and IL-33 -/- intervention groups (n = 5); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Journal: Acta Cirúrgica Brasileira

Article Title: Effect of IL-33 on pyroptosis of macrophages in mice with sepsis via NF-κB/p38 MAPK signaling pathway

doi: 10.1590/ACB360501

Figure Lengend Snippet: Content of inflammatory factors detected via ELISA. (a) Content of IL-33; (b) Content of IL-1β; (c) content of IL-18. Content of IL-33,IL-1β, and IL-18 in the serum of mice in sham operation, model, IL-33 -/- , and IL-33 -/- intervention groups (n = 5); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Article Snippet: After operation, recombinant murine IL-33 (TransGen Biotech™, Beijing, China) was intraperitoneally injected into the mice at 0.5 mg/kg in the IL-33 -/- intervention group, while the same volume of normal saline was injected into the mice in the model group, the sham operation group, and the IL-33 -/- group.

Techniques: Enzyme-linked Immunosorbent Assay

Expression level of pyroptosis-related proteins in macrophages of mice. (a) Bands; (b) statistical graph. The expression level of pro-caspase-1 p10 in macrophages of mice in sham operation, model, IL-33 -/- ,and IL-33 -/- intervention groups (n = 5); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Journal: Acta Cirúrgica Brasileira

Article Title: Effect of IL-33 on pyroptosis of macrophages in mice with sepsis via NF-κB/p38 MAPK signaling pathway

doi: 10.1590/ACB360501

Figure Lengend Snippet: Expression level of pyroptosis-related proteins in macrophages of mice. (a) Bands; (b) statistical graph. The expression level of pro-caspase-1 p10 in macrophages of mice in sham operation, model, IL-33 -/- ,and IL-33 -/- intervention groups (n = 5); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Article Snippet: After operation, recombinant murine IL-33 (TransGen Biotech™, Beijing, China) was intraperitoneally injected into the mice at 0.5 mg/kg in the IL-33 -/- intervention group, while the same volume of normal saline was injected into the mice in the model group, the sham operation group, and the IL-33 -/- group.

Techniques: Expressing

Expression level of NF-κB/p38 MAPK signaling pathway-related proteins in macrophages of mice determined by means of Western blotting. (a) Bands; (b) statistical graph of IκB-α; (c) statistical graph of NF-κB p65; (d) statistical graph of p-p38 MAPK. The expression levels of IκB-α and NF-κB p65 proteins of mice in sham operation, model, IL-33 -/- , and IL-33 -/- intervention groups (n = 5); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Journal: Acta Cirúrgica Brasileira

Article Title: Effect of IL-33 on pyroptosis of macrophages in mice with sepsis via NF-κB/p38 MAPK signaling pathway

doi: 10.1590/ACB360501

Figure Lengend Snippet: Expression level of NF-κB/p38 MAPK signaling pathway-related proteins in macrophages of mice determined by means of Western blotting. (a) Bands; (b) statistical graph of IκB-α; (c) statistical graph of NF-κB p65; (d) statistical graph of p-p38 MAPK. The expression levels of IκB-α and NF-κB p65 proteins of mice in sham operation, model, IL-33 -/- , and IL-33 -/- intervention groups (n = 5); && p < 0.01 vs. sham operation group; ^^ p < 0.01 vs. model group; ## p < 0.01 vs. IL-33 -/- group.

Article Snippet: After operation, recombinant murine IL-33 (TransGen Biotech™, Beijing, China) was intraperitoneally injected into the mice at 0.5 mg/kg in the IL-33 -/- intervention group, while the same volume of normal saline was injected into the mice in the model group, the sham operation group, and the IL-33 -/- group.

Techniques: Expressing, Western Blot